Key points from article :
GammaDelta Therapeutics will test its T-cell therapy in a clinical trial expected to begin later this year.
The trial will assess the safety of treatment and look for early indications of efficacy in people with acute myeloid leukaemia (AML).
Currently has four treatments in its pipeline, two of which are focused on treating haematological malignancies like blood cancer.
These cells make up only a small number of all the T cells in the body.
GammaDelta says they have distinct properties that give them promise as a potential cancer therapy.
They scan the surface of cells directly to spot potential threats.
Could help treat patients whose cancer cells have tried to evade the immune system by removing certain molecules from their surface, making them invisible to alpha beta T cells.
“From our very first studies...these immune cells have enormous potential for the development of new immunotherapy treatments,” - Adrian Hayday, scientific founder of GammaDelta.
